Background and Aims: Biosimilar infliximab CT-P13 received European Medicines Agency [EMA] approval in June 2013 for all indications of the originator product. In the present study, we aimed to evaluate the predictors of short-and medium-term clinical outcome in patients treated with the biosimilar infliximab at the participating inflammatory bowel disease [IBD] 
Introduction
Biosimilar infliximab CT-P13 was approved by the European Medicines Agency [EMA] in 2013 and by the Food and Drug Administration [FDA] in 2016 for use in all indications of the originator infliximab. 1, 2 The use of biosimilar infliximab is mandatory in Hungary since May 2014 in all new inflammatory bowel disease [IBD] patients, including anti-tumour necrosis factor [TNF]-naïve patients and in patients who were previously successfully treated with the originator product but had been on drug holiday for at least 12 months. Data on the efficacy, safety, and immunogenicity of the biosimilar infliximab in IBD from real-life cohort studies published so far showed comparable outcomes to those of the originator product. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] The efficacy of anti-TNF therapy in Crohn's disease [CD] has been reported to be associated with shorter disease duration, isolated colonic disease location, absence of previous surgery, young age, and non-smoking status. 15 High C-reactive protein [CRP] level [≥ 0.8 mg/dl] at start of the infliximab therapy was associated with corticosteroid-free clinical remission at Week 26 in CD patients. 16 In the study by García-Bosch et al., higher albumin level was predictve of clinical remission at Week 8 (odds ratio [OR] 1.4, 95% confidence interval [CI] 1.06-1.8; p = 0.017], whereas clinical remission at Week 8 was the only independent predictor for maintained clinical remission at Weeks 30 and 54 in ulcerative colitis [UC] patients treated with infliximab. Previous cyclosporine therapy, absence of concomitant immunomodulator, and absence of response at Week 8 were associated with a higher colectomy rate at Week 54. 17 The use of therapeutic drug monitoring [TDM] has become widespread in management of patients receiving biological therapy. CD patients with loss of response [LOR] to infliximab had significantly lower infliximab trough levels [TLs] and higher anti-drug antibody [ADA] levels compared with responders [cut-off values for identifying LOR: < 0.5 μg/ml for infliximab TL and ≥ 10 U/ml for ADA]. 18 The rate of clinical remission was higher in CD patients with detectable infliximab TLs compared with patients with undetectable serum infliximab TLs after a median of 14 infusions [82% vs 6%; p < 0.001]. 19 In the TAXIT [Trough level Adapted infliximab Treatment] trial, IBD patients were assigned to groups receiving infliximab either based on their clinical activity or based on their TL after reaching the target infliximab concentration [3-7 μg/ml]. No significant difference was found between the TDM-based strategy and clinically-based dosing in achieving clinical remission after 1 year. However, TDM-based dosing was associated with fewer flares during follow-up. 20 According to the findings of the Tailored  Treatment With Infliximab for Active Crohn's Disease [TAILORIX] study, trough-level based and symptom-driven dose adaptation did not differ in terms of the proportion of CD patients being in steroidfree clinical remission from Week 22 to Week 54 and in endoscopic remission at Week 54. 21 Until now, few data are available on the predictive potential of the infliximab TL and ADA status in IBD patients treated with infliximab. In a post hoc analysis of a multicentre, prospective trial with the originator infliximab, TLs at Week 2 were significantly associated with Weeks 14 and 30 clinical remission and mucosal healing at Week 30 in UC. 22 Therefore, in the present study we aimed to prospectively identify the predictors of short-and medium-term clinical outcome in patients treated with the biosimilar infliximab CT-P13 in a nationwide cohort of IBD patients. In addition to clinical factors, the predictive potential of biochemical markers and serial TDM samples were also evaluated.
Materials and Methods
The inclusion period of this prospective, nationwide, multicentre, observational study started in May 2014 at 12 IBD centres in Hungary. Unselected, consecutive IBD patients starting on biosimilar infliximab were prospectively enrolled. No patient received originator infliximab during the 12 months preceding the initiation of biosimilar infliximab therapy. A harmonised monitoring strategy was applied as requested by the Hungarian National Health Fund [ Disease location and disease behaviour in CD and disease extent in UC were classified according to the Montreal classification. 23 In CD, clinical remission was defined as a CDAI < 150 points or no fistula drainage as assessed by the Fistula Drainage Assessment, and clinical response was defined as a decrease in CDAI of more than 70 points or at least 50% reduction in the number of draining fistulas. 24, 25 In UC, clinical remission was defined as a pMayo of less than three points and clinical response was defined as a decrease in the pMayo score with more than three points 26 . 6 The detection cut-off value of biosimilar infliximab TL was 0.1 μg/ml, and 3-7 μg/ml was defined as therapeutic. At Weeks 2 and 6, cut-off values of biosimilar infliximab TL were calculated by ROC analysis. The standard cut-off value of ADA level was 10 ng/ml. The cut-off value of CRP was 10 mg/l. Due to cohort size, the predictive potential of clinical and biochemical factors at Week 54 were calculated in CD, but not in UC. 
Statistical considerations

Results
A total of 291 consecutive IBD patients─184 patients with CD and 107 patients with UC─were enrolled in the study. Patient characteristics are shown in . Sensitivity, specificity, PPV, and NPV were also calculated.
[ Table 3 
Discussion
This is the first report on the predictive value of TL levels and ADA status in IBD patients treated with biosimilar infliximab in a prospective, nationwide, multicentre IBD cohort. In UC, TLs measured at Week 2 were associated with clinical response and remission at both Weeks 14 and 30, whereas ADA development at Week 14 was inversely associated with clinical response at Week 30.
These results are in agreement with previous observations in UC patients treated with the originator infliximab therapy, where TL ≥ 20.7 ug/l at Week 2 was significantly associated with clinical remission Weeks 14 and 30. 22 A retrospective study from a tertiary referral centre investigated the association between early TLs and short-term mucosal healing [STMH] 28 According to the results of the post hoc analysis of the ACT-1 and ACT-2 [Active Ulverative Colitis Trials] trials, serum infliximab levels at Weeks 8, 30, and 54 were significantly in higher in UC patients being in clinical response and/or remission or having mucosal healing compared with patients having lower infliximab levels. Furthermore, patients with lower infliximab levels were more likely to fail to maintain clinical efficacy compared with patients with higher infliximab levels. 29 In CD, Week 2 TL was associated and ADA positivity was inversely associated with clinical remission at Week 14. In contrast, 32, 33 High-sensitivity CRP [hs-CRP] positivity at diagnosis might be a helpful marker also for patient classification, as it was associated with colonic and ileocolonic disease location and non-inflammatory disease behaviour and with the need for azathioprine or biological therapy during the later disease course. In addition, in patients having elevated hs-CRP level at diagnosis, hs-CRP was an independent predictor for clinical relapse at 3 and 12 months. 34 In the post hoc analysis of A Crohn's Disease Clinical Trial Evaluating Infliximab in a New Long-term Treatment 35 In another post hoc analysis of the ACCENT I trial, high baseline CRP level [cut-off points of 0.7-2.5 mg/ dl] was associated with maintenance of clinical remission through 54 weeks of infliximab therapy. Normal Week-14 CRP levels, with cut-off points of 0.5, 0.6, 0.7, and 0.9 mg/ dl, were significantly associated with maintained clinical response, whereas the absolute reduction of CRP level between baseline and Week 14 was significantly associated with the maintenance of clinical response and remission between Weeks 14 and 54. 36 We found no association between other investigated clinical factors such as gender, disease behaviour, disease extent, concomitant steroid/azathioprine therapy, and the clinical outcomes in IBD patients on biosimilar infliximab therapy. Similarly, Seow et al. reported no effect of concurrent immunosuppressive therapy on clinical remission and colectomy rates in a cohort of 115 UC patients on infliximab therapy. 28 In contrast, in the study by Papamichael et al., univariate analysis identified female gender [p = 0.039] and concomitant immunomodulators at start of infliximab [p = 0.028] as variables associated with short-term mucosal healing in UC patients. 27 Of note, previous anti-TNF exposure was inversely associated with clinical remission at Weeks 14, 30 and 54 in CD, whereas in UC, previous anti-TNF exposure was only associated with short-term clinical outcomes. In the previous study of our study group enrolling 210 IBD patients on biosimilar infliximab therapy, clinical remission rates were also influenced by previous exposure to the originator infliximab in bothCD and UC at Week 14 but not at Week 30 [at Week 14 clinical remission with no previous exposure vs previous exposure to the originator infliximab: CD: 60.9% vs 35.7% p < 0.05, UC: 65.1% vs 33.3%, p < 0.05 and p < 0.05, at Week 30: CD: 60% vs 38.9%, p = 0.13, UC: 78.9% vs 33.3%, p = 0.06]. 6 The main strengths of the present study are the prospective data collection and the standardised, harmonised monitoring strategy. So far, the predictive value of TL and ADA level in IBD patients receiving biosimilar infliximab therapy has not been studied. Limitations of our study are that TDM measurement at Weeks 2 and 6 was not mandatory and only selected centres participated. Furthermore, endoscopic evaluation was not performed at Week 14 or 30 and predictive potential was evaluated compared with clinical and biochemical remission criteria. Of note, the assay was not able to detect ADA in the presence of drug, which may have influenced the ADA clinical outcome associations as suggested in recent publications. 37 In conclusion, TL measured at Week 2 might be an important factor in the prediction of short-and medium-term clinical efficacy in UC and short-term clinical outcomes in CD patients treated with biosimilar infliximab. Further prospective studies are needed to determine the role of TDM in the prognosis of the clinical efficacy of biosimilar infliximab therapy. In addition, previous anti-TNF exposure has been proven to be a relevant factor associated with clinical efficacy throughout the 54-week treatment period in CD, whereas it was associated only with short-term clinical outcomes in UC. 
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